Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on IDEAYA Biosciences (IDYA – Research Report). The associated ...

Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

The following is a summary of “Survival in uveal melanoma patients is linked to genetic variation at HERC2 SNP rs12913832,” published in the September 2024 issue of Ophthalmology by Gelmi et al. Uveal ...

Retired teacher Debbie Hensley learned that a freckle in the back of her eye turned cancerous and led her to have a detached retina. She was diagnosed with a rare form of eye cancer called uveal ...

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

(IDYA) Monday announced positive interim data from a Phase 2 study evaluating darovasertib as neoadjuvant treatment for uveal melanoma (UM). Neoadjuvant therapy is given to a patient before the ...

Uveal melanoma (UM) is a rare melanoma originating in the eye’s uvea, with 50% of patients experiencing metastasis predominantly in the liver. In contrast to cutaneous melanoma, there is only a ...

IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...

Ideaya Biosciences Inc. (NASDAQ:IDYA), a precision medicine oncology company, released interim Phase 2 clinical trial data.

Crizotinib is under clinical development by Pfizer and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II drugs for Uveal Melanoma have a 29% phase transition success rate ...